169 related articles for article (PubMed ID: 29777361)
21. Audiological follow-up in transplant patients treated with calcineurin immunosuppressants "Calcineurin inhibitors and Ototoxicity".
Heider C; Waissbluth S; Oyarzún J; Calderara G; Leung JS; Novoa I
Rev Med Chil; 2023 Jun; 151(6):702-710. PubMed ID: 38801378
[TBL] [Abstract][Full Text] [Related]
22. Neurotoxicity of calcineurin inhibitors: impact and clinical management.
Bechstein WO
Transpl Int; 2000; 13(5):313-26. PubMed ID: 11052266
[TBL] [Abstract][Full Text] [Related]
23. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
24. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
25. Effects of calcineurin inhibitors on paraoxonase and arylesterase activity after a kidney transplant.
Kahvecioglu S; Ersoy A; Gullulu M; Dirican M
Exp Clin Transplant; 2014 Aug; 12(4):334-42. PubMed ID: 24447269
[TBL] [Abstract][Full Text] [Related]
26. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation.
Arora-Gupta N; Davies P; McKiernan P; Kelly DA
Pediatr Transplant; 2004 Apr; 8(2):145-50. PubMed ID: 15049794
[TBL] [Abstract][Full Text] [Related]
27. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
Liver Transpl; 2006 May; 12(5):762-7. PubMed ID: 16528713
[TBL] [Abstract][Full Text] [Related]
28. Tailoring tacrolimus therapy in kidney transplantation.
Jouve T; Noble J; Rostaing L; Malvezzi P
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):581-588. PubMed ID: 29779413
[TBL] [Abstract][Full Text] [Related]
29. The association between tacrolimus exposure and tremor, headache and insomnia in adult kidney transplant recipients: A systematic review.
King CP; Cossart AR; Isbel NM; Campbell SB; Staatz CE
Transplant Rev (Orlando); 2024 Jan; 38(1):100815. PubMed ID: 38071930
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
Baek CH; Kim JH; Yu H; Shin E; Cho H; Kim H; Yang WS; Han DJ; Park SK
Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
[TBL] [Abstract][Full Text] [Related]
31. Effect of steroid-free low concentration calcineurin inhibitor maintenance immunosuppression regimen on renal allograft histopathology and function.
Nainani N; Patel N; Tahir N; Kumar R; Weber-Shrikant E; Gundroo AA; Murray BM; Tornatore KM; Blessios GA; Venuto RC
Nephrol Dial Transplant; 2012 May; 27(5):2077-83. PubMed ID: 22058172
[TBL] [Abstract][Full Text] [Related]
32. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime.
Whalen HR; Glen JA; Harkins V; Stevens KK; Jardine AG; Geddes CC; Clancy MJ
Transplantation; 2017 Feb; 101(2):430-436. PubMed ID: 26950724
[TBL] [Abstract][Full Text] [Related]
33. Sensorineural Deafness Following Tacrolimus Use.
Lakshmi BS; Vidya B; Reddy MHK; Kumar ACV; Ram R; Kumar VS
Exp Clin Transplant; 2020 Feb; 18(1):110-111. PubMed ID: 29969081
[TBL] [Abstract][Full Text] [Related]
34. Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.
Camilleri B; Bridson JM; Halawa A
Exp Clin Transplant; 2016 Oct; 14(5):471-483. PubMed ID: 27213490
[TBL] [Abstract][Full Text] [Related]
35. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
36. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
[TBL] [Abstract][Full Text] [Related]
37. Nuclear Factor of Activated T Cells-Regulated Gene Expression as Predictive Biomarker of Personal Response to Calcineurin Inhibitors.
Sommerer C; Giese T
Ther Drug Monit; 2016 Apr; 38 Suppl 1():S50-6. PubMed ID: 26418701
[TBL] [Abstract][Full Text] [Related]
38. [Pharmacovigilance of calcineurin inhibitor in peidatric kidney and liver transplantation].
Riva N; Cáceres Guido P; Rousseau M; Dip M; Monteverde M; Imventarza O; Mato G; Schaiquevich P
Farm Hosp; 2013; 37(6):441-9. PubMed ID: 24256007
[TBL] [Abstract][Full Text] [Related]
39. Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling.
Diémé B; Halimi JM; Emond P; Büchler M; Nadal-Desbarat L; Blasco H; Le Guellec C
Transplantation; 2014 Jul; 98(2):195-201. PubMed ID: 24598938
[TBL] [Abstract][Full Text] [Related]
40. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
